The KRAS mutation is found in several cancers such as pancreatic cancer, colorectal cancer, lung cancer, bile duct cancer and thyroid cancer. The existence of KRAS mutations is often associated with a prognostic marker of drug response. For example, the KRAS mutation is considered a strong prognostic marker for drug response to tyrosine kinase inhibitors such as Gefitinib (Iressa) or Erlotinib (Tarceva). Recently, KRAS mutation is often detected in colorectal cancer and may be related to drug response to Cetuximab (Erbitux) or Panitumumab (Vectibix) used for colon cancer therapy. Therefore, KRAS mutation testing is necessary to determine drug resistance in patients with colorectal or lung cancer and will be useful for anticancer therapies.
PANAMutyper™ R KRAS
To detect KRAS mutations and determine their response to various treatments in colon cancer.
Cat. No. PNAR-1001
Other products
9K Series Plasmid Miniprep Kit – 9K-006-0010
Plasmid purification kit: the Bio Basic Plasmid DNA extraction kit...
PathoSEEK® RT-qPCR Master Kit (200 rxns)
Real-time quantitative reverse transcription PCR (qRT-PCR or RT-qPCR) is a...
TRIS HYDROCHLORIDE
Tris hydrochloride is used as a buffer component for DNA...
Strip tubes – CP0111
200 uL tubes for qPCR in white strip with transparent...